- Interviews with patients from the VenoValve® pivotal study
IRVINE, CA / ACCESSWIRE / November 16, 2023 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today...
- $51.4 million cash on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025
- Live video webcast interactive Q&A with participating companies -
Live moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Wednesday, October 25th at 12:00 PM ET
- 18 VenoValve patients enrolled over the final two months of the study
- enVVe development cycle to be reduced by 6 months
Up to an additional $34 million of capital may become available from milestone-driven warrants in Q2, 2024 upon the release of initial topline efficacy data from the VenoValve pivotal trial
IRVINE, CA / ACCESSWIRE / July 8, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced...
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.